KRAS and familial pancreatic carcinoma: Selecting two pancreatic cancer cell lines, PANC-1 and MiaPaCa-2, as the study cells, the siRNA delivery capability and the K-ras silencing efficacy of CPCHC-44 can be systematically evaluated (Scheme 1).